Related Experiment Video

Updated: Mar 31, 2026

Important Endpoints and Proliferative Markers to Assess Small Intestinal Injury and Adaptation using a Mouse Model of Chemotherapy-Induced Mucositis
07:05

Important Endpoints and Proliferative Markers to Assess Small Intestinal Injury and Adaptation using a Mouse Model of Chemotherapy-Induced Mucositis

Published on: May 12, 2019

6.7K

Safety and Dosing Study of Glucagon-Like Peptide 2 in Children With Intestinal Failure

David L Sigalet1, Mary Brindle1, Dana Boctor2

  • 11 Pediatric Surgery, Alberta Children's Hospital, University of Calgary, Alberta, Canada.

JPEN. Journal of Parenteral and Enteral Nutrition
|October 17, 2015
PubMed

Insights

Glucagon-like peptide 2 (GLP-2) was safely administered to children with intestinal failure, showing a pharmacokinetic profile similar to adults. Further trials are recommended to explore its nutritional benefits in pediatric patients.

Area of Science:

  • Pediatric Gastroenterology
  • Clinical Pharmacology
  • Nutritional Science

Background:

  • Glucagon-like peptide 2 (GLP-2) analogue approved for adult intestinal failure.
  • No prior studies of GLP-2 in pediatric populations.
  • Urgent need to evaluate GLP-2 in children with intestinal failure.

Purpose of the Study:

  • Examine the pharmacokinetics of GLP-2 in pediatric patients.
  • Assess the safety and tolerability of GLP-2 in children.
  • Investigate the nutritional effects of GLP-2 in pediatric intestinal failure.

Main Methods:

  • Open-label trial involving 7 parenteral nutrition-dependent pediatric patients.
  • Subcutaneous GLP-2 administration at 20 µg/kg/d for up to 42 days.
  • Follow-up to 1 year to assess long-term effects.

Main Results:

  • GLP-2 was well tolerated with no significant adverse events or vital sign changes.
  • Pharmacokinetic profile in children mirrored that of adults.
  • Numeric improvements in nutritional indices (z scores, citrulline) observed.

Conclusions:

  • GLP-2 is safe and well-tolerated in pediatric patients with intestinal failure.
  • Pharmacokinetics in children are comparable to adults.
  • Larger trials are warranted to confirm nutritional efficacy in pediatric populations.
Abstract

Keywords:
adaptationdipeptidyl peptidase IVnecrotizing enterocolitispharmacokinetics

More Related Videos

Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices06:34

Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices

Published on: November 29, 2024

677
Sustained Administration of β-cell Mitogens to Intact Mouse Islets Ex Vivo Using Biodegradable Poly(lactic-co-glycolic acid) Microspheres09:31

Sustained Administration of β-cell Mitogens to Intact Mouse Islets Ex Vivo Using Biodegradable Poly(lactic-co-glycolic acid) Microspheres

Published on: November 5, 2016

7.8K

Related Concept Videos

Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.3K
Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
1.3K
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
1.2K
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
732
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
769
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
332